Company Overview
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company dedicated to the development and commercialization of therapies designed to improve vision within the United States market. The enterprise functions within the Healthcare sector, specifically categorized under the Biotechnology industry, which implies a focus on scientific innovation and the creation of novel medical treatments. This biotechnology firm employs a workforce of 152 individuals to execute its strategic objectives regarding presbyopia treatments. The company currently holds a market capitalization of $283.80M, generating annual revenue of $19.09M based on trailing twelve-month figures. These valuation and revenue metrics indicate that LENZ maintains a mid-cap position in the biotechnology landscape, reflecting a significant investment from the market despite operating with a relatively lean employee base of 152 people.
Financial Health
The company reported a revenue of $19.09M for the trailing twelve months, while the net income stood at -$82,127,000 and the EBITDA was -$90,851,000. The substantial gap between the positive revenue of $19.09M and the negative net income reveals a cost structure characterized by high operational expenses or research and development costs that far exceed current income generation. Free cash flow for the period was -$40,249,248, indicating that the company is consuming cash reserves to fund its operations and growth initiatives rather than generating surplus liquidity. The gross margin is reported at 97.8%, suggesting high efficiency in the cost of goods sold relative to revenue, though this is partially offset by the negative operating margin of -2422.1% and a profit margin of 0.0%. The balance sheet shows a cash position of $292.35M against total debt of $815,000, resulting in a debt-to-equity ratio of 0.29, which suggests a highly conservative and low-leveraged financial structure. This liquidity is further supported by a current ratio of 14.23, indicating an exceptionally strong ability to meet short-term obligations with available current assets. Return on equity is -33.6% and return on assets is -21.9%, metrics that reveal the company is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common characteristic for early-stage biotechnology firms focused on product development.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the absence of net income, while the forward P/E is -4.22, which implies that analysts project earnings to remain negative in the near future based on the current stock price. The price-to-book ratio is 1.00, indicating that the market values the company at exactly its book value, suggesting no significant market premium or discount relative to the tangible assets on the balance sheet. Alternative valuation metrics show a price-to-sales ratio of 14.87 and an EV/EBITDA of 0.08, suggesting that investors are pricing the stock based on sales potential rather than current earnings power or cash flow generation. The stock has traded between a 52-week high of $50.40 and a 52-week low of $8.99, providing a wide range of volatility over the past year. Without a specific current price provided in the available facts to calculate the exact percentage relative to the high, the stock's position within this $41.41 range highlights the inherent risk and reward profile typical of small-cap biotechnology equities. The beta value is 1.76, which indicates that the stock price is expected to be 76% more volatile than the broader market, reflecting heightened sensitivity to market movements and sector-specific news.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct calculation of whether earnings are growing faster or slower than revenue in the most recent period. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all earnings to reinvest into research, development, and commercialization efforts rather than distributing income to shareholders. This strategy of retaining earnings is consistent with the capital-intensive nature of the biotechnology industry, where funding product pipelines is prioritized over immediate income distribution. Consequently, the overall growth and income profile for LENZ Therapeutics, Inc. is defined by significant cash consumption and an absence of dividend income, relying entirely on future commercial success and external capital to sustain operations.